Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 其他文獻 > Item 310902500/24254

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24254

Title:	Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study
Authors:	Sheikh, S;Wei, CC;Tegzova, D;Stohl, W;de Toledo, RA;Mucenic, T;Banfi, MA;Maksimowicz-McKinnon, K;Abud-Mendoza, C;Navarra, S;Garcia, M;Garcia-De La Torre, I;Kurrasch, R;Fernandes, S;Harris, J;Muzaffar, S;Fox, NL;Liu, A;Quasny, H;Roth, D
Date:	2021
Issue Date:	2022-08-05T10:45:34Z (UTC)
Publisher:	WILEY
ISSN:	2326-5191
URI:	https://www.webofscience.com/wos/woscc/full-record/WOS:000744545205084 https://ir.csmu.edu.tw:8080/handle/310902500/24254
Relation:	ARTHRITIS & RHEUMATOLOGY ,2021 ,v73 ,p2699-2699
Appears in Collections:	[中山醫學大學研究成果] 其他文獻

Files in This Item:

There are no files associated with this item.